A Phase 1 interventional study of AZD2389 in Hepatic Impairment, sponsored by AstraZeneca. Completed at 5 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by AstraZeneca · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Lymphoma, Follicular by AstraZeneca — 4 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Follicular · AstraZeneca.
Among the 17 studies in Lymphoma, Follicular by AstraZeneca, this one is the 10th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 1, and was the 15th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →4 of the 17 studies in Lymphoma, Follicular by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States
Ages 18–85 · Healthy volunteers
AstraZeneca · Sites in United States, Australia, Brazil and 13 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Canada and 7 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Belgium and 22 more countries
Ages 18–130
By country, each count listing its studies:
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 7 · Phase 3 2
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 130 across the 16 interventional studies, 1,182 across the 1 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
1 of the studies in Lymphoma, Follicular by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07546760AstraZenecaA Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 | 2027-02-04 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Lymphoma, Follicular by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.
This is a single-dose, non-randomised, open-label, parallel-group study to examine the PK, fibroblast activation protein activity, safety, and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.
The study is planned to consist of:
Safety, tolerability, and available plasma PK data up to 48 hours post-dose from at least 4 participants in each of the mild hepatic impairment (CP Class A) and moderate hepatic impairment (CP Class B) cohorts must have been assessed by the investigator(s), medical monitor, and sponsor prior to the decision to proceed with evaluation/recruitment of participants with severe hepatic impairment (CP Class C). Cohort 1 (normal hepatic function) will be initiated in parallel with Cohorts 2 and 3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Hepatic:
For Healthy:
All participants:
- Body weight ≥ 50 kg; within the range of 18.0 to 42.0 kg/m2 (inclusive).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with normal hepatic function (sex-, age-, and body mass index \[BMI\]-matched)
Drug: AZD2389
Participants with mild hepatic impairment (CP A classification)
Drug: AZD2389
Participants with moderate hepatic impairment (CP B classification)
Drug: AZD2389
Participants with severe hepatic impairment (CP C classification)
Drug: AZD2389
Single oral dose of AZD2389 in participants from all cohorts
Plasma PK parameter Cmax
maximum observed plasma concentration
Time frame: pre-dose to 48 hours post-dose
Plasma PK parameter AUCinf
area under the concentration-time curve from zero to infinity
Time frame: pre-dose to 48 hours post-dose
Plasma PK parameter AUClast
area under the concentration-time curve from zero to the last measurable concentration
Time frame: pre-dose to 48 hours post-dose
Plasma PK parameter t1/2λz
half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve
Time frame: pre-dose to 48 hours post-dose
Plasma PK parameter Tmax
time to reach maximum observed plasma concentration
Time frame: pre-dose to 48 hours post-dose
Plasma PK parameter CL/F
apparent total body clearance of drug from plasma after extravascular administration
Time frame: pre-dose to 48 hours post-dose
Plasma PK parameter Vz/F
apparent volume of distribution during the terminal phase after extravascular administration.
Time frame: pre-dose to 48 hours post-dose
Urine PK parameter Ae(t1-t2)
cumulative amount of unchanged drug excreted into the urine for the interval between time 1 and time 2
Time frame: pre-dose to 48 hours post-dose
Urine PK parameter CLr
renal clearance of the drug from plasma
Time frame: pre-dose to 48 hours post-dose
Urine PK parameters fe(t1-t2)
fraction of the drug excreted into the urine for the interval between time 1 and time 2
Time frame: pre-dose to 48 hours post-dose
Ran from Feb 2025 to primary completion in Sep 2025, 7 months.
Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Follicular, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 71. This study's 7 months is below that.
Counting every sponsor, half of 173 studies reached it within 51 months; a quarter within 30 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD2389